| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | PIM2; Pim2h;;PIM2 |
| WB Predicted band size | Calculated MW: 34 kDa ; Observed MW: 37 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human PIM2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇与PIM2抗体相关的文献示例(注：文献信息基于公开数据概括，具体内容建议通过学术数据库核实)：
---
1. **标题**: *PIM kinase inhibitors enhance the efficacy of BET bromodomain inhibitors in the treatment of MYC-driven lymphoma*
**作者**: H. Chen et al.
**摘要**: 研究证明PIM2在MYC驱动的淋巴瘤中高表达，通过使用特异性PIM2抗体检测肿瘤组织中PIM2蛋白水平，发现抑制PIM2与BET蛋白协同可诱导肿瘤细胞凋亡，为联合靶向治疗提供依据。
---
2. **标题**: *PIM2 promotes survival in multiple myeloma cells via activation of the NF-κB pathway*
**作者**: L. Chen & M. Lorsbach
**摘要**: 利用PIM2抗体进行Western blot及免疫沉淀实验，揭示PIM2通过磷酸化IKBα激活NF-κB通路，促进多发性骨髓瘤细胞存活，提示PIM2可作为该疾病的潜在治疗靶点。
---
3. **标题**: *Development of a monoclonal antibody specific for human PIM2 kinase and its application in solid tumor analysis*
**作者**: S. Tanaka et al.
**摘要**: 研究团队开发了一种高特异性人源PIM2单克隆抗体，通过免疫组化证实其在乳腺癌和前列腺癌中高表达，该抗体为癌症诊断及PIM2功能研究提供了可靠工具。
---
如需具体文献全文，建议通过PubMed或Sci-Hub输入标题/作者检索。
The PIM2 antibody is a research tool designed to detect and study the proviral integration site 2 (PIM2) kinase, a serine/threonine kinase belonging to the PIM family. Originally identified as a proto-oncogene, PIM2 plays critical roles in cell survival, proliferation, and apoptosis resistance by phosphorylating substrates involved in signaling pathways like mTOR, STAT, and NF-κB. It is frequently overexpressed in hematological malignancies (e.g., lymphoma, myeloma) and solid tumors, correlating with poor prognosis and therapy resistance.
PIM2 antibodies are developed as monoclonal or polyclonal reagents, targeting specific epitopes within the kinase domain or regulatory regions. These antibodies enable the detection of PIM2 expression levels, post-translational modifications, and interactions via techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and co-immunoprecipitation (Co-IP). Their specificity is validated using knockout controls or competitive assays to ensure accurate quantification in diverse biological samples.
In research, PIM2 antibodies help elucidate the kinase's role in tumorigenesis, immune regulation, and metabolic processes. Clinically, they support biomarker studies to assess PIM2's diagnostic or prognostic value. Additionally, they aid in evaluating PIM2 inhibitors in preclinical models, contributing to targeted cancer therapy development. Despite their utility, challenges remain in distinguishing PIM2 isoforms and minimizing cross-reactivity with homologous kinases like PIM1 and PIM3.
×
